Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004198 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004198: Completed Phase 2 study, sponsored by University of Nebraska.
NCT00004198 is a Phase 2 study that has completed, run by University of Nebraska. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004198, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells. Sargramostim may stimulate a person's immune system and help to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy plus sargramostim following chemotherapy in treating patients who have stage III or stage IV non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL keyhole limpet hemocyanin
- BIOLOGICAL tumor cell-based vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06-25 |
| Est. Completion | 2003-11-20 |
| Phase | Phase 2 |
What the finished NCT00004198 record still lists
NCT00004198 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00004198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004198 about?
NCT00004198 is a clinical study titled "Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells. Sargramostim may stimulate a person's immune system and help to kill tumor cells. PURPOSE: Phase II trial ...
What is the current status of trial NCT00004198?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-06-25. Estimated completion is 2003-11-20.
What interventions are being tested in trial NCT00004198?
The interventions under investigation include: sargramostim (BIOLOGICAL), keyhole limpet hemocyanin (BIOLOGICAL), tumor cell-based vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004198?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI